Could a higher dose of an Alzheimer's drug boost thinking skills in down syndrome?
NCT ID NCT07531940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test whether higher-than-standard doses of memantine, a drug already approved for Alzheimer's, are safe and tolerable in 25 adolescents and young adults with Down syndrome. The study also looks for early signs that the drug might improve memory and thinking. It is a first step toward a larger trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospitals Case Medical Center
Cleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new tests unlock hidden cognitive changes in down syndrome?
- Tiny exercise bursts might sharpen minds in intellectual disability
- Could a Self-Help guide transform parenting stress for families of kids with NDD?
- Bubble cushions may boost balance in down syndrome
- Beyond the genome: new Multi-Omics approach aims to crack the code of intellectual disability
- Can a common ADHD drug help kids with down syndrome?